Regeneron Launches $200 Million Donation Matching Program to Support Vision Care
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best S&P 500 stocks with huge upside potential.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 578,889 | $367,148,770 | +16% | 0.33% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 553,800 | $351,236,574 | 0.79% | |
| 3. | Squarepoint Ops LLC Maxime Fortin (Cio) | 284,003 | $180,123,223 | +12% | 0.22% |
| 4. | AQR Capital Management Cliff Asness | 235,950 | $148,664,871 | +14% | 0.15% |
| 5. | 228,000 | $144,604,440 | +36% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | $1,245,286.62 | 23,880,537 | 2017-08-25 | Filing | |
| $485.99 | 2,681 | $1,302,949.65 | 23,877,980 | 2017-08-25 | Filing | |
| $485.28 | 5,723 | $2,777,256.30 | 23,875,299 | 2017-08-25 | Filing | |
| $484.21 | 2,000 | $968,420.00 | 23,869,576 | 2017-08-25 | Filing | |
| $482.87 | 4,485 | $2,165,687.20 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $844.61 | 1,000 | $844,610.00 | 12,931 | 2024-11-01 | Filing | |
| $1,059.28 | 2 | $2,118.56 | 17,582 | 2024-10-01 | Filing | |
| $1,057.38 | 2 | $2,114.76 | 17,584 | 2024-10-01 | Filing | |
| $1,056.68 | 3 | $3,170.04 | 17,586 | 2024-10-01 | Filing | |
| $1,054.90 | 3 | $3,164.70 | 17,589 | 2024-10-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,407,891 | $5,966,766,709 | 0.11% | |
| 2. | 8,925,880 | $5,661,061,035 | 0.12% | |
| 3. | 7,598,584 | $4,819,250,174 | 0.31% | |
| 4. | 5,658,197 | $3,588,599,008 | 0.26% | |
| 5. | 4,789,659 | $3,037,745,428 | 0.13% |
News See All
12 Best S&P 500 Stocks With Huge Upside Potential
Bankim Chadha, Deutsche Bank's chief global strategist, joined CNBC's 'The Exchange' on June 24 to express a cautionary view regarding further monetary policy movement despite recent positive inflation...
UBS Lowers Price Target On Regeneron Pharmaceuticals, Inc. (REGN).
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has maintained its Neutral rating on Regeneron Pharmaceuticals, Inc.
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Regeneron Pharmaceuticals, Inc. (REGN) Growth Story Shifts as Wells Fargo Maintains Hold
On June 10, 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price target at $580.
7 52-Week Low Dividend Stocks to Consider
Since 2023, dividend stocks have faced challenges and have yet to regain momentum.
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now.
11 Most Profitable NASDAQ Stocks to Buy Now
Earlier on May 30, Siebert Financial CIO Mark Malek appeared on CNBC to discuss the tariff headwinds swirling around the markets and which sectors could then rise above the noise and continue to perform...
8 Best Inexpensive Stocks to Buy Right Now
On June 7, Torsten Slok, Apollo Global Management, joined 'Closing Bell Overtime' on CNBC to discuss the US jobs report and the broader economic landscape.
JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc.
Billionaire Hedge Funds
